Company: AGIO
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001439222-25-000009
Chunk: 447

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 1
Chunk 447
---
 an unrealized loss position at December 31, 2024 and 2023 was $768.1 million and $513.5 million, respectively. There were no individual securities that were in a significant unrealized loss position as of December 31, 2024 and 2023. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of December 31, 2024 and 2023.

Note 5. Inventory

Inventory, which consists of commercial supply of PYRUKYND®, consisted of the following:(In thousands)December 31, 2024December 31, 2023Raw materials$89 $51 Work-in-process24,509 17,568 Finished goods3,018 1,457 Total inventory$27,616 $19,076 

Note 6. Leases

Our building leases are comprised of office and laboratory space under non-cancelable operating leases. These lease agreements have remaining lease terms of three years and contain various clauses for renewal at our option. The renewal options were not included in the calculation of the operating lease assets and the operating lease liabilities as the renewal options are not reasonably certain of being exercised. The lease agreements do not contain residual value guarantees. We currently lease approximately 146,000 square feet at 88 Sidney Street, 43,000 square feet at 64 Sidney Street, and 13,000 square feet at 38 Sidney Street, Cambridge, Massachusetts. All leases, as amended, expire on February 29, 2028. At the end of the initial lease period, we have the option to extend the leases at all facilities for two consecutive five-year periods at the fair market rent at the time of the extension.The components of lease expense and other information related to leases were as follows:(In thousands)202420232022Operating lease costs$15,227 $15,227 $15,227 Cash paid for amounts included in the measurement of operating lease liabilities18,705 18,170 17,035 We have not entered into any material short-term leases or financing leases as of December 31, 2024.

F-17

In arriving at the operating lease liabilities as of December 31, 2024, we applied the weighted-average incremental borrowing rate of